US 11,891,368 B2
Benzothia(di)azepine compounds and their use as bile acid modulators
Per-Göran Gillberg, Åsbro (SE); Ingemar Starke, Gothenburg (SE); and Santosh S. Kulkarni, Bangalore (IN)
Assigned to Albireo AB, Gothenburg (SE)
Filed by Albireo AB, Gothenburg (SE)
Filed on Feb. 10, 2022, as Appl. No. 17/668,640.
Application 17/668,640 is a division of application No. 17/144,622, filed on Jan. 8, 2021, granted, now 11,267,794.
Application 17/144,622 is a continuation of application No. PCT/EP2020/084570, filed on Dec. 4, 2020.
Claims priority of application No. 201911049984 (IN), filed on Dec. 4, 2019.
Prior Publication US 2022/0162176 A1, May 26, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 285/36 (2006.01); A61P 1/16 (2006.01)
CPC C07D 285/36 (2013.01) [A61P 1/16 (2018.01)] 17 Claims
 
1. A method for treating a disease or disorder in a subject, the method comprising administering to the subject a therapeutically effective amount of a compound of formula (I),

OG Complex Work Unit Chemistry
wherein M, R1, R2, R3, R4 and R5 are as indicated in Table 1 below:
TABLE 1
 
M R1 R2 R3 R4 R5
 
CH2 CH2CH2CH2CH3 CH2CH2CH2CH3 F SCH3 F
CH2 CH2CH2CH2CH3 CH2CH3 F SCH3 H
CH2 CH2CH2CH2CH3 CH2CH3 F SCH3 F
NH CH2CH2CH2CH3 CH2CH3 F SCH3 H
NH CH2CH2CH2CH3 CH2CH3 F SCH3 F
NCH3 CH2CH2CH2CH3 CH2CH3 F SCH3 H
NCH3 CH2CH2CH2CH3 CH2CH3 F SCH3 F
CH2 CH2CH2CH3 CH2CH3 H SCH3 H
CH2 CH2CH2CH3 CH2CH3 H SCH3 F
CH2 CH(CH3)2 CH2CH3 H SCH3 H
CH2 CH(CH3)2 CH2CH3 H SCH3 F
CH2 CH2CH2CH2CH3 CH2CH3 F SCH2CH3 H
CH2 CH2CH2CH2CH3 CH2CH3 F SCH2CH3 F
NH CH2CH2CH2CH3 CH2CH3 H SCH2CH3 H
NH CH2CH2CH2CH3 CH2CH3 H SCH2CH3 F
NH CH2CH2CH2CH3 CH2CH3 F SCH2CH3 H
NH CH2CH2CH2CH3 CH2CH3 F SCH2CH3 F
NCH3 CH2CH2CH2CH3 CH2CH3 H SCH2CH3 H
NCH3 CH2CH2CH2CH3 CH2CH3 H SCH2CH3 F
NCH3 CH2CH2CH2CH3 CH2CH3 F SCH2CH3 H
NCH3 CH2CH2CH2CH3 CH2CH3 F SCH2CH3 F
CH2 CH2CH2CH2CH3 CH2CH3 F Cl H
CH2 CH2CH2CH2CH3 CH2CH3 F Cl F
NH CH2CH2CH2CH3 CH2CH3 H Cl H
NH CH2CH2CH2CH3 CH2CH3 H Cl F
NH CH2CH2CH2CH3 CH2CH3 F Cl H
NH CH2CH2CH2CH3 CH2CH3 F Cl F
NCH3 CH2CH2CH2CH3 CH2CH3 H Cl H
NCH3 CH2CH2CH2CH3 CH2CH3 H Cl F
NCH3 CH2CH2CH2CH3 CH2CH3 F Cl H
NCH3 CH2CH2CH2CH3 CH2CH3 F Cl F
CH2 CH2CH2CH2CH3 CH2CH3 F N(CH3)2 H
CH2 CH2CH2CH2CH3 CH2CH3 F N(CH3)2 F
NH CH2CH2CH2CH3 CH2CH3 H N(CH3)2 H
NH CH2CH2CH2CH3 CH2CH3 H N(CH3)2 F
NH CH2CH2CH2CH3 CH2CH3 F N(CH3)2 H
NH CH2CH2CH2CH3 CH2CH3 F N(CH3)2 F
NCH3 CH2CH2CH2CH3 CH2CH3 H N(CH3)2 H
NCH3 CH2CH2CH2CH3 CH2CH3 H N(CH3)2 F
NCH3 CH2CH2CH2CH3 CH2CH3 F N(CH3)2 H
NCH3 CH2CH2CH2CH3 CH2CH3 F N(CH3)2 F
CH2 CH2CH2CH2CH3 CH2CH3 Cl SCH3 F
NH CH2CH2CH2CH3 CH2CH3 Cl SCH3 F
NCH3 CH2CH2CH2CH3 CH2CH3 Cl SCH3 F
CH2 CH2CH2CH2CH3 CH2CH3 Cl Cl F
NH CH2CH2CH2CH3 CH2CH3 Cl Cl F
NCH3 CH2CH2CH2CH3 CH2CH3 Cl Cl F
CH2 CH2CH2CH2CH3 CH2CH3 Cl N(CH3)2 F
NH CH2CH2CH2CH3 CH2CH3 Cl N(CH3)2 F
NCH3 CH2CH2CH2CH3 CH2CH3 Cl N(CH3)2 F
 
or a pharmaceutically acceptable salt thereof, wherein the disease or disorder is selected from the group consisting of: a cardiovascular disease; a disorder of fatty acid metabolism; a glucose utilization disorder; a gastrointestinal disease or disorder; a liver disease or disorder; a hyperabsorption syndrome; hypervitaminosis and osteopetrosis; hypertension; glomerular hyperfiltration; or pruritus of renal failure.